Applied Innovation Review Issue No. 2 June 2016
Authors: Vladimir V. Senatorov, Christopher B. Eiben, Nisreen M. A. Hejab, Aaron R. Friedman
Palisade Therapeutics is a new venture with a novel therapeutic approach for treating progressive neurological diseases, with a focus on post-traumatic epilepsy and age-related dementia, two unmet clinical markets with a value estimated at $30 billion. Current drugs suffer from two major shortcomings: they are not personalized and they are not disease-modifying; in other words, they manage symptoms without understanding or treating the underlying causes of neurodegeneration.